Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination

  • Rosell, R
  • Cao, Peng
  • Cai, Xueting
  • Xing, Baojuan
  • Ito, Masaoki
  • Gomez-Vazquez, Jose Luis
  • Marco-Jordán, Mireia
  • Calabuig-Farinas, Silvia
  • Cardona, Andrés F.
  • Codony-Servat, Jordi
  • Gonzalez, Jessica
  • València-Clua, Kevin
  • Aguilar, Andrés
  • Pedraz-Valdunciel, Carlos
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
[EN] Background KRAS-mutant non-small cell lung cancer (NSCLC) shows a relatively low response rate to chemotherapy, immunotherapy and KRAS-G12C selective inhibitors, leading to short median progression-free survival, and overall survival. The MET receptor tyrosine kinase (c-MET), the cognate receptor of hepatocyte growth factor (HGF), was reported to be overexpressed in KRAS-mutant lung cancer cells leading to tumor-growth in anchorage-independent conditions. Methods Cell viability assay and synergy analysis were carried out in native, sotorasib and trametinib-resistant KRAS-mutant NSCLC cell lines. Colony formation assays and Western blot analysis were also performed. RNA isolation from tumors of KRAS-mutant NSCLC patients was performed and KRAS and MET mRNA expression was determined by real-time RT-qPCR. In vivo studies were conducted in NSCLC (NCI-H358) cell-derived tumor xenograft model. Results Our research has shown promising activity of omeprazole, a V-ATPase-driven proton pump inhibitor with potential anti-cancer properties, in combination with the MET inhibitor tepotinib in KRAS-mutant G12C and non-G12C NSCLC cell lines, as well as in G12C inhibitor (AMG510, sotorasib) and MEK inhibitor (trametinib)-resistant cell lines. Moreover, in a xenograft mouse model, combination of omeprazole plus tepotinib caused tumor growth regression. We observed that the combination of these two drugs downregulates phosphorylation of the glycolytic enzyme enolase 1 (ENO1) and the low-density lipoprotein receptor-related protein (LRP) 5/6 in the H358 KRAS G12C cell line, but not in the H358 sotorasib resistant, indicating that the effect of the combination could be independent of ENO1. In addition, we examined the probability of recurrence-free survival and overall survival in 40 early lung adenocarcinoma patients with KRAS G12C mutation stratified by KRAS and MET mRNA levels. Significant differences were observed in recurrence-free survival according to high levels of KRAS mRNA expression. Hazard ratio (HR) of recurrence-free survival was 7.291 (p = 0.014) for high levels of KRAS mRNA expression and 3.742 (p = 0.052) for high MET mRNA expression. Conclusions We posit that the combination of the V-ATPase inhibitor omeprazole plus tepotinib warrants further assessment in KRAS-mutant G12C and non G12C cell lines, including those resistant to the covalent KRAS G12C inhibitors., This work was supported by grants from Spanish Association Against Cancer (AECC) grant (PROYE18012ROSE) and National Natural Science Foundation of China (No. 82125037). National NaturalScience Foundation of China (No. 82125037), Jiangsu Provincial Medical Innovation Center (CXZX202225), the New High School 20 Items Project of Jinan (202333006) and the Taishan Scholars Program (tstp 20231239).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo científico (JournalArticle)

HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer

  • Gonzalez-Cao, Maria
  • Cai, Xueting
  • Bracht, Jilian Wilhelmina Paulina
  • Han, Xuan
  • Yang, Yang
  • Pedraz-Valdunciel, Carlos
  • Morán, Teresa
  • García-Corbacho, Javier
  • Aguilar, Andrés
  • Bernabé, Reyes
  • De Marchi, Pedro
  • da Silva, Luciane Sussuchi
  • Ferro Leal, Leticia
  • Reis, Rui Manuel
  • Codony-Servat, Jordi
  • Jantus-Lewintre, Eloisa|||0000-0001-7395-4380
[EN] Purpose: High-mobility group box 1 protein (HMGB1) is subject to exportin 1 (XPO1)-dependent nuclear export, and it is involved in functions implicated in resistance to immunotherapy. We investigated whether HMGB1 mRNA expression was associated with response to immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC). Patients and Methods: RNA was isolated from pretreatment biopsies of patients with advanced NSCLC treated with ICI. Gene expression analysis of several genes, including HMGB1, was conducted using the NanoString Counter analysis system (PanCancer Immune Profiling Panel). Western blotting analysis and cell viability assays in EGFR and KRAS mutant cell lines were carried out. Evaluation of the antitumoral effect of ICI in combination with XPO1 blocker (selinexor) and trametinib was determined in a murine Results: HMGB1 mRNA levels in NSCLC patients treated with ICI correlated with progression-free survival (PFS) (median PFS 9.0 versus 18.0 months, P=0.008, hazard ratio=0.30 in high versus low HMGB1). After TNF-alpha stimulation, HMGB1 accumulates in the cytoplasm of PC9 cells, but this accumulation can be prevented by using selinexor or antiretroviral drugs. Erlotinib or osimertinib with selinexor in EGFR-mutant cells and trametinib plus selinexor in KRAS mutant abolish tumor cell proliferation. Selinexor with a PD-1 inhibitor with or without trametinib abrogates the tumor growth in the murine Lewis lung cancer model. Conclusion: An in-depth exploration of the functions of HMGB1 mRNA and protein is expected to uncover new potential targets and provide a basis for treating metastatic NSCLC in combination with ICI., The investigators wish to thank the patients for kindly agreeing to donate samples to this study. We also thank all the physicians who collaborated by providing clinical information. This work was supported by a European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement ELBA [No 765492] , the National Science Foundation for Distinguished Young Scholars [82125037] , the Major National Science and Technology Program of China for Innovative Drug [2017ZX09101002-002-006] , and by the Key R&D Program of Jiangsu Province [BE2018755, HBZ2021-012] . This work was also partially supported by a Spanish Association Against Cancer (AECC) grant (PROYE18012ROSE) and by the Public Ministry of Labor Campinas (Research, Prevention, and Education of Occupational Cancer) . This work is in memory of the generous support provided by the late Julian Santamaria Valino to the IOR Foundation.r the Public Ministry of Labor Campinas (Research, Prevention, and Education of Occupational Cancer) . This work is in memory of the generous support provided by the late Julian Santamaria Valino to the IOR Foundation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impact of the APE1 Redox Function Inhibitor E3330 in Non-Small Cell Lung Cancer Cells Exposed to Cisplatin, Increased Cytotoxicity and Impairment of Cell Migration and Invasion

  • Manguinhas, Rita
  • Fernandes, Ana S.|||0000-0001-6350-0641
  • Costa, João G.|||0000-0002-5604-6142
  • Saraiva, Nuno|||0000-0003-1333-9137
  • Camões, Sérgio P.|||0000-0003-0355-5338
  • Gil, Nuno|||0000-0002-6567-8379
  • Rosell, Rafael|||0000-0003-0817-3400
  • Castro, Matilde
  • Miranda, Joana P.|||0000-0002-7804-4068
  • Oliveira, Nuno G.
Elevated expression levels of the apurinic/apyrimidinic endonuclease 1 (APE1) have been correlated with the more aggressive phenotypes and poor prognosis of non-small cell lung cancer (NSCLC). This study aimed to assess the impact of the inhibition of the redox function of APE1 with E3330 either alone or in combination with cisplatin in NSCLC cells. For this purpose, complementary endpoints focusing on cell viability, apoptosis, cell cycle distribution, and migration/invasion were studied. Cisplatin decreased the viability of H1975 cells in a time- and concentration-dependent manner, with IC values of 9.6 µM for crystal violet assay and 15.9 µM for 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. E3330 was clearly cytotoxic for concentrations above 30 µM. The co-incubation of E3330 and cisplatin significantly decreased cell viability compared to cisplatin alone. Regarding cell cycle distribution, cisplatin led to an increase in sub-G1, whereas the co-treatment with E3330 did not change this profile, which was then confirmed in terms of % apoptotic cells. In addition, the combination of E3330 and cisplatin at low concentrations decreased collective and chemotactic migration, and also chemoinvasion, by reducing these capabilities up to 20%. Overall, these results point to E3330 as a promising compound to boost cisplatin therapy that warrants further investigation in NSCLC.